The accelerator is betting big on 4 key areas:
- Software development guardrails that de-risk "vibe coding"
- Web-browsing agents
- Backend workflow automation
- Vertical agents penetrating highly regulated industries like healthcare and finance
The timing is critical. 2025 funding to software development AI agents has already outpaced 2024 by 3x, while 32% of verticalized AI agent companies are actively deploying solutions in hard-to-penetrate regulated sectors.
As backend automation moves beyond simple workflows and regulated industries embrace AI agents, the companies that master these areas will define the next wave of enterprise software.
See which agentic AI categories are primed for breakout growth in our full analysis of Y Combinator's Spring 2025 batch.
Not: Novo Nordisk breaks up with Hims & Hers
Novo Nordisk terminated its telehealth partnership with Hims & Hers on Monday, citing illegal mass sales of Wegovy knockoffs. Hims & Hers’ stock plummeted 34% while Novo’s dropped 5% following the news.
After launching the partnership in April to expand Wegovy access post-shortage, Novo accused Hims of selling cheaper, unapproved versions under "false personalization" claims instead of steering patients to the real drug.
The breakup suggests Novo is willing to sacrifice distribution partnerships to protect premium pricing — a risky move as Eli Lilly’s rival GLP-1 medications continue to make market share gains.
CB Insights customers can see how Novo's $33B manufacturing push and strategic investments stack up in our breakdown of the GLP-1 powerhouse.